These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 36746513)

  • 1. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
    Schoutrop E; Poiret T; El-Serafi I; Zhao Y; He R; Moter A; Henriksson J; Hassan M; Magalhaes I; Mattsson J
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin-Specific CAR T Cells Target Ovarian Cancer.
    Schoutrop E; El-Serafi I; Poiret T; Zhao Y; Gultekin O; He R; Moyano-Galceran L; Carlson JW; Lehti K; Hassan M; Magalhaes I; Mattsson J
    Cancer Res; 2021 Jun; 81(11):3022-3035. PubMed ID: 33795251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.
    Schoutrop E; Renken S; Micallef Nilsson I; Hahn P; Poiret T; Kiessling R; Wickström SL; Mattsson J; Magalhaes I
    Oncoimmunology; 2022; 11(1):2093426. PubMed ID: 35898704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude.
    Poiret T; Vikberg S; Schoutrop E; Mattsson J; Magalhaes I
    J Transl Med; 2024 Mar; 22(1):273. PubMed ID: 38475830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
    Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
    Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
    J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
    Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
    Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
    Guo J; Zeng X; Zhu Y; Yang D; Zhao X
    J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.
    McCarthy D; Lofgren M; Watt A; Horton H; Kieffer-Kwon P; Ding J; Kobold S; Baeuerle PA; Hofmeister R; Gutierrez DA; Tighe R
    Cancer Immunol Immunother; 2023 Dec; 72(12):4195-4207. PubMed ID: 37848682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
    Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
    Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
    Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.
    Zhang Q; Liu G; Liu J; Yang M; Fu J; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Zhang L; Tian X
    Mol Ther Oncolytics; 2021 Mar; 20():556-568. PubMed ID: 33738341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.